Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

    Powerful effects seen in all subjects including those with low HDL -
    representing a majority of myocardial infarct patients

    TSX Exchange Symbol: RVX

CALGARY, Sept. 29 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that results from the Company's Phase 1b/2a clinical trial have met and exceeded expectations by successfully concluding the drug, RVX-208, is safe and tolerable. Most importantly RVX-208 has met its primary endpoint to increase the production of plasma ApoA-I, the key cardioprotective protein in high-density lipoprotein (HDL), often referred to as "good" cholesterol. ApoA-I is generally endorsed as a key protective factor against atherosclerosis and cardiovascular disease with 40% of all first heart attack patients having low ApoA-I.

Resverlogix's Phase 1b/2a study tested RVX-208 for 28 days in three different dosing arms. The most pronounced results were demonstrated among those subjects with low HDL cholesterol levels. Low HDL is an important risk factor in coronary and cardiovascular disease patients. Resverlogix will continue to build upon its world leading position in development of novel small molecules that increase ApoA-l production and reverse cholesterol transport (RCT) markers in patients with high vascular risk profiles. RCT is a path by which cholesterol on the arterial wall is transported back to the liver by ApoA-I lipid complexes for excretion. Additional analysis was performed on other key RCT markers which achieved high levels of statistical significance. The Company has established a dosing range that it deems will be safe, well tolerated and effective for Phase 2 intravascular ultrasound (IVUS) development trials.

"The range of increase in ApoA-l production of all subjects, but in particular low HDL subjects over placebo demonstrated in this study is one of the most significant pieces of data for RVX-208. We have excee
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... , A major pan-European survey ... delivery of care has revealed changing trends in many ... the provision of healthcare services across the continent. The ... European Gastroenterology (UEG), have been announced today and led ... the burden of GI disorders across Europe ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... March 16 Micromet, Inc. (Nasdaq: MITI ), ... of cancer, inflammation and autoimmune diseases, today announced the publication ... meeting of AACR taking place from April 20-24, 2009, in ... , Lutterbuese, ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... of innovative therapeutic products for the treatment of cancer, ... a notice from the NASDAQ Hearings Panel that Oncothyreon ... of The NASDAQ Global Market. , The notice followed ...
... take two bricks and place them side by side a ... the bricks will be covered with snow and barely discernible. ... around the bricks. , What you will see, says Ivan ... smallest of scales on an integrated optical circuit, could hasten ...
Cached Biology Technology:Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 2Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 3Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 4Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 5Oncothyreon regains compliance with NASDAQ listing requirements 2New organic material may speed Internet access 2New organic material may speed Internet access 3New organic material may speed Internet access 4New organic material may speed Internet access 5
(Date:10/15/2014)... have linked increased resistance to bacterial pneumonia in female ... hormone estrogen. , Females are naturally more resistant to ... scientists has shown that increased resistance to bacterial pneumonia ... oxide synthase 3 (NOS3). They also show that this ... female sex hormone estrogen. , The team, lead by ...
(Date:10/15/2014)... be awarded the 44th Rosenstiel Award for Distinguished Work ... research exploring the mechanisms of genomic instability and its ... is the second alumnus to win the Rosenstiel Award; ... 2003. , Alt is the Charles A. Janeway Professor ... School and an investigator at the Howard Hughes Medical ...
(Date:10/14/2014)... thieves, prostate cancer tumors scavenge and hoard copper that ... avarice may be a fatal weakness. , Researchers ... prostate cancer cells by delivering a trove of copper ... cells brimming with the mineral, leaving non-cancer cells healthy. ... commercially available for other uses, could soon be tested ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... MANHATTAN, KAN. -- New findings about the causes of ... genetic. "We now know it,s also in the ... Professor of Diagnostic Medicine and Pathobiology at Kansas State ... ago, Richt said, it was thought that the cattle ...
... Neurons constituting the optic nerve wire up to the ... developing retina sprout processes, called axons, which extend toward visual ... U-turns when they take the wrong path. How they find ... Using the mouse visual system, a team of Salk ...
... CITY After years of working toward this goal, scientists ... isolate cancer stem cells in tumors so they can target ... A research team at the University of Oklahoma led ... a particular protein only appears in stem cells. Until now, ...
Cached Biology News:K-State professor's USDA research shows mad cow disease also caused by genetic mutation 2A second career for a growth factor receptor: keeping nerve axons on target 2A second career for a growth factor receptor: keeping nerve axons on target 3
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
p-Raf-1 (Ser 338/Tyr 341)-R...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: